MedTrace Logo

Dose-escalation, Repeated and Single Oral Dosing Study

NCT02419820 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2019-02-15

No results posted yet for this study

Summary

Randomized, Double-blind, Placebo-controlled, Dose-escalation, Repeated and Single Oral Dosing Phase I Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of APD791 (Temanogrel) Co-administered with Aspirin and Clopidogrel.

Conditions

  • Acute Coronary Syndrome

Interventions

DRUG

APD791

Temanogrel

DRUG

Clopidogrel

Clopidogrel

DRUG

Aspirin

Aspirin

DRUG

Placebo for APD791

Placebo for APD791

Sponsors & Collaborators

  • Asan Medical Center

    collaborator OTHER

  • IlDong Pharmaceutical Co Ltd

    lead INDUSTRY

Principal Investigators

  • Gyunseop Bae, M.D. · Asan Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2016-04-30
Completion
2016-04-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02419820 on ClinicalTrials.gov